Heather J. Hinton

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Journal: Nature medicine

Published: January 17, 2026

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

Journal: Nature medicine

Published: December 15, 2025

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.

Journal: Blood neoplasia

Published: December 16, 2024

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 16, 2024

Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications.

Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications.

Journal: Clinical and translational science

Published: August 26, 2022

Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.

Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.

Journal: Cancer chemotherapy and pharmacology

Published: July 14, 2022

Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.

Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.

Journal: Journal of pharmaceutical sciences

Published: August 20, 2021

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.

Journal: Breast cancer research and treatment

Published: April 22, 2021

Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.

Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.

Journal: Cytokine: X

Published: May 04, 2020

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.

Journal: Journal of autoimmunity

Published: July 31, 2018

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 13, 2018

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Journal: Oncoimmunology

Published: October 26, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026